Form 4: Orchestra BioMed CEO Buys 5,000 Shares

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman purchased 5,000 shares of common stock at a weighted average price of $4.07.

Summary

• David P. Hochman, the Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), purchased 5,000 shares of the company's common stock.
• The transaction occurred on November 14, 2025, at a weighted average price of $4.07 per share, with individual transaction prices ranging from $4.06 to $4.10.
• Following this purchase, Hochman directly beneficially owns 612,822 shares of Orchestra BioMed Common Stock.
• He also indirectly beneficially owns 442,765 shares through the DPH 2008 Trust, 2,000 shares through the Solomon Ascher Hochman 2019 Trust, 2,000 shares through the Hannah Hochman 2019 Trust, 2,000 shares through the Judah Herman Hochman 2019 Trust, and 3,140 shares through the NSH 2008 Family Trust.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 8

Explanation: The CEO's direct purchase of company stock indicates strong confidence in the company's valuation and future prospects, which is generally a bullish signal for investors.

Positives

• The CEO and Chairperson, David P. Hochman, increased his direct ownership in Orchestra BioMed Holdings, Inc. by purchasing 5,000 shares, signaling confidence in the company's future.
• Insider buying, particularly by top management, is often interpreted as a bullish indicator, suggesting management believes the stock is undervalued or has strong growth potential.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned investment decision rather than a reaction to immediate market events.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, as it primarily reports an insider stock transaction.

Industry Context

This Form 4 filing reports a specific insider transaction and does not provide broader industry trends or competitive analysis. However, insider buying can be a signal of management's perception of the company's position within its industry.

Related Party Transactions

• David P. Hochman indirectly beneficially owns shares through several family trusts: DPH 2008 Trust (442,765 shares), Solomon Ascher Hochman 2019 Trust (2,000 shares), Hannah Hochman 2019 Trust (2,000 shares), Judah Herman Hochman 2019 Trust (2,000 shares), and NSH 2008 Family Trust (3,140 shares).

Stakeholder Impact

• Shareholders: May view the CEO's purchase as a positive signal of management's confidence in the company's future, potentially increasing investor interest and demand for the stock.

Key Dates

Recommendation

The CEO's direct purchase of company stock, especially a significant amount, signals strong confidence in the company's valuation and future performance. This insider buying activity is a positive indicator that seasoned investors often consider when evaluating a stock, suggesting potential upside.

Keywords

Orchestra BioMed Holdings, OBIO, David P Hochman, CEO, Insider Trading, Stock Purchase, Form 4, Beneficial Ownership, Equity Investment, Rule 10b5-1